revive pharmacy semaglutide is a FDA-approved GLP-1 receptor agonist used to improve blood sugar control in type 2 diabetes (Ozempic, Rybelsus) and for chronic weight management (Wegovy). It mimics a hormone that stimulates insulin Semaglutide / Glycine – WP

Dual-Hormone Action on Appetite Tirzepatide activates both GLP-1 and GIP receptors in the brain, leading to a stronger reduction in hunger and food cravings than single-agonist drugs

Scaling laws predict global microbial diversity

Evidence references ADJUNCT ONE, PMID 27506222 ADJUNCT TWO, PMID 27493132 ADJUST T1D, PMID 40550013 Semaglutide crossover study, PMID 39794615 Tirzepatide observational data (Shah 2024), PMC11571402 Shah discontinuation post-hoc (ADJUNCT I/II), PMID 39717993 Shah 2025, GLP-1RA / tirzepatide in T1D with severe early (genetic) obesity ( JDST ) Insulin titration paper, PMID 39829697 Adjunct therapy review, PMID 40618954 Bone health review, PMC8118128 Weight loss and bone, PMID 38916894 Consensus and guidelines: ADA Standards 2025, PMID 39651989 ISPAD 2024, PMID 39657603 GLP-1 AID consensus, PMID 39517127 Related reading on GNL This Episode 17 conversation was the inspiration for the four-part Adjunctive Therapies guide built on top of the April 2026 evidence update

This is consistent with broader research showing that behavioural support significantly improves pharmacological weight-loss outcomes

Whats less often discussed is that the number on the scale doesnt tell the full story